

# SEE YOUR DOCTOR

## A New Advanced Treatment May Be Your Key To Parenthood

(NAPSA)—Are you among the ten percent of Americans of child-bearing age who want to start a family but face the daunting reality of infertility?

Although it is comforting to know that promising infertility treatments are available, you may be overwhelmed by the options, the process and the costs.

Now there is a new, highly effective, convenient treatment that may be your answer to parenthood. Bravelle™ (urofollitropin for injection, purified), recently approved by the U.S. Food and Drug Administration, is a highly purified, naturally derived follicle-stimulating hormone that stimulates the development of eggs in the ovaries, an important step in most infertility treatment programs.

The new treatment can be administered by either subcutaneous (SC) or intramuscular (IM) administration. Most patients prefer SC administration, where you self-inject the medication just under the skin with much smaller needles than IM.

It is also the lowest priced purified gonadotropin—an important benefit since infertility treatment is generally not fully covered by insurance. Since cost may limit the number of treatment cycles a patient can pursue, the savings can translate into additional treatment cycles, which can increase the possibility of parenthood.

Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe Bravelle™. Like all gonadotropins, it is a potent substance capable of causing mild to severe adverse reactions, including ovarian hyperstimulation syndrome (incidence of 8.2 percent), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. Like other products for ovarian stimulation, treatment may result in multiple gestations.

For more information about infertility, visit [www.ferringfertility.com](http://www.ferringfertility.com).